Kissing Many Frogs: A Grimm Tale or Necessary Reality When Precision Fundraising in Biotech is Out of Reach?
The future of biotech fundraising may not belong to companies that pitch to the most investors. It will more likely belong to those that understand which investors are most likely to become long-term partners and how to navigate to them efficiently. In fundraising, as in medicine, precision is beating trial and error.